DelNS1-2019-nCoV-RBD-OPT1 / University of Hong Kong, Xiamen University, Yangshengtang - LARVOL DELTA

Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults (clinicaltrials.gov) - P4 | N=10000 | Not yet recruiting | Sponsor: Jiangsu Province Centers for Disease Control and Prevention

New P4 trial • Infectious Disease • Novel Coronavirus Disease

To Evaluate Safety & Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 for COVID-19 in Healthy Adults Received 2 Doses of BNT162b2 (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: The University of Hong Kong | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • IFNG

To Evaluate Safety & Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 for COVID-19 in Healthy Adults Received 2 Doses of BNT162b2 (clinicaltrials.gov) - P2; N=150; Not yet recruiting; Sponsor: The University of Hong Kong

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease • IFNG

BRIEF-Beijing Wantai Biological Pharmacy Begins Phase 1 Clinical Study For Coronavirus Vaccine Candidate (Thomson Reuters Foundation) - "SAYS IT HAS PARTNERED WITH XIAMEN UNIVERSITY AND UNIVERSITY OF HONG KONG TO DEVELOP A VACCINE CANDIDATE AGAINST COVID-19; SAYS THE VACCINE CANDIDATE HAS BEEN APPROVED BY CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR CLINICAL TRIAL IN HUMANS; SAYS IT HAS BEGUN PHASE 1 CLINICAL STUDY FOR CORONAVIRUS VACCINE CANDIDATE."

Licensing / partnership • Trial status • Infectious Disease • Novel Coronavirus Disease